ReviewCureus2025
The Role of Eyelid Margin Vascularity in Meibomian Gland Dysfunction Diagnosis and Management.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Anteroplacement of the Mucocutaneous Junction and Goblet Cell Expansion: Microanatomic Remodeling of the Human Eyelid Margin.Investigative ophthalmology & visual science · 2026Article
- Presence of Eyelid Disease in Habitual Scleral Lens Wearers.Journal of clinical medicine · 2026Article
- Utilization of Matrix Metalloproteinase-9 Point-of-Care Immunoassay for Meibomian Gland Dysfunction Evaluation in Glaucoma Patients.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review investigates the diagnostic and prognostic significance of telangiectatic meibomian gland dysfunction (MGD), as well as potential therapeutic approaches. A thorough scientific literature search was conducted using various databases. Studies focusing on eyelid vascular changes in MGD published between 2010 and 2024 were reviewed. Paper selection was based on their contribution to the understanding of the pathophysiology, diagnosis, and management of the disease. Ocular surface inflammation, oxidative stress, and cytokine activity are the main molecular pathways involved in the pathophysiology of MGD, which leads to increased eyelid margin vascularity. Newer imaging techniques, especially swept-source optical coherence tomography angiography (SS-OCTA), have enabled quantification and objective visualization of this pathology. Additionally, the classification of MGD into telangiectatic and non-telangiectatic forms aids in treatment customization. Promising treatments targeting vascular abnormalities, such as intense pulsed light (IPL), anti-vascular endothelial growth factor (VEGF) agents, and cyclosporine, have emerged to improve meibomian gland function and reduce inflammation. Eyelid margin vascularity is an important biomarker for the diagnosis and management of MGD. With improved imaging techniques and targeted treatments, clinicians can more precisely evaluate disease severity and offer more effective interventions. Further research is needed to standardize diagnostic criteria, customize treatment protocols, and investigate new therapeutic targets for clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.